Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
The Pharma Data
SEPTEMBER 16, 2020
New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation.
Let's personalize your content